EXUMA's rPOC platform gives CAR-T cell therapy wings.

Dr. Greg Frost is a scientist, researcher, entrepreneur and co-founder of two biotech companies.
currently the Chairman and CEO of EXUMA Biotechnology, a clinical biotech company dedicated to the discovery and development of CAR-T therapies for blood tumors and solid tumors.
1999, as a young entrepreneur, Frost co-founded Halozyme Therapeutics, a listed biotech company focused on tumor biologics and drug delivery, with initial capital investments.
halozyme, he brings the company's founding platform technology and has led the development of a number of biotechnology products, from discovery to FDA approval.
2002, he was appointed Chief Scientific Officer and in December 2010 he was appointed Ceo.
, Forbes named Dr. Frost one of the 20 most powerful CEOs in the United States.
halozyme in 2014, he led the health division of Intrexon Corporation, a multinational listed biotech company, to expand its oncology franchise, as well as gene- and cell-based orphan disease therapies.
has written several scientific peer reviews and guest articles and is the inventor of key patents supporting FDA-approved biological products.
. Frost has identified a number of key points for CAR-T cell therapy, especially as his rapid point of care (rPOC) platform provides a significant speed-up for these treatments.
Last year, EXUMA Biotechnology and its subsidiary Shanghai PerHum Therapeutics today released the interim results of two car-T products for the recurrence or treatment of stage IV metastatic renal cell carcinoma (mRCC).
the above data, announced at the 2019 meeting of the Society for Cancer Immunotherapy (CIMT), continue to support studies on the safety, dose climbing, pharmacogenic dynamics and preliminary effectiveness of CCCT301-38 (AXL) and CT301-59 (ROR2) products in a single patient population

The umbrella clinical trial was designed under the guidance of lead clinical researcher Dr. Zhu Tongyu at SPHCC (Shanghai Public Health Clinical Center) to study the first two CAR-T products in human clinical trials using "and" logic door control techniques.
the logic gate design has the advantage of utilizing tumor microencourse (TME) to convert acidic TME that inhibits growth into an activation signal, thus minimizing the possibility of targeting and de-tumor activity.
triggers for this logic gate are TME and the other is target antigen (AXL or ROR2, depending on the product).
key points published by the United States Government include: no dose-restrictive toxicity has been observed to date, and no target and detoxatoxicity can be attributed to both products.
up to 80,000 copies/micrograms of blood genomic DNA were observed at the 1 x 106/kg dose level.
early radiological evidence of anti-tumor activity suggests that the best response is disease stabilization.
the patient group had previously used a variety of treatments, with 6 of the 7 subjects surviving with a medium follow-up period of 140 days.
the above interim results continue to support the company's Conditional Active Biologics (CAB)-CAR-T technology, which is expected to enhance the safety of CAR-T therapeutic drugs in metastatic renal cell carcinoma (mRCC, and hopefully other target-positive solid tumors). "The cell processing feasibility, cell exposure and initial safety of these two new products support the possibility of CAB-CAR-T technology being used for solid tumors," said Wendy Li, chief medical officer of
Essoma Biotech.
we look forward to a complete data set from the ongoing clinical studies and collaborators mentioned above, and to bringing these projects to multi-center research in the future.
" innovative technology to make CAR-T easier for CAR-T cell therapy because of preparation difficulties, management complexity, coupled with hospital costs, can cost more than $1 million per patient.
, CAR-T works well, but security is still a problem and a big challenge.
the product safe enough for you to be able to get the patient home after car-T? In addition, can you skip or simplify the lymphocytic extraction process, essentially removing existing T cells before applying CAR-T, making room for CAR-T cells to expand and grow in the body? This is not an optimized experience, as it often creates challenges beyond late cytokine storms, which is also a big problem.
, in the long run, cell therapy programs will face huge challenges unless they can improve the process, which is exactly what we EXUMA is doing.
rPOC could make CAR-T easier, potentially significantly reducing CAR-T production costs and greatly simplifying the delivery of healthcare systems.
first, this approach, using the existing tumor infusion infrastructure, can be used to extract self-contained T cells from patients and achieve efficacy through clearer pathways, which greatly reduces cost and complexity.
in animal models, we can intravenously treat CAR-T cells intravenously in less than 12 hours without the need for lymphatic removal, which could be a huge breakthrough.
this may require longer hospital stays than other procedures.
simply eliminating extended hospital stays will greatly reduce patient costs and increase access.
, this product also helps to overcome solid tumors.
for CAR-T, blood tumors are three different from solid tumors.
, CAR-T cells and normal tissues expressing low-level CAR-T targets have a targeted, non-tumor toxicity, or potentially reactive risk.
The second problem is the heterogoglymity of many solid tumors, in many solid tumors, it may not be 100% of cancer cells can find a target, allowing the so-called 'antigen escape', that is, tumor cells that do not express the target antigen to escape the elimination of targeted treatment.
problem is that many solid tumors are hostile to the tumor micro-environment, and the cancer becomes its own 'organ' that can resist the immune system's entry.
EXUMA uses the unique properties of TME to amplify the CAR-T signal as the CAR-T cells approach the tumor.
in other words, we use a negative attribute of TME to 'turn on' our CAR-T cells.
this way, we can more safely target antigens present in normal tissues because CAR-T cells remain 'off' when they are not near the tumor.
the team is currently working hard to advance the technology.
that the approach we have taken, although very different from some other approaches to the development of CAR-T technology, is beginning to show significant progress.
passion for the work our team of scientists and researchers is doing.
think that ultimately, if successful, we can have a huge impact on advancing patient care, which could have something to do with the next 20 years."
source: MedSci !-- end of content presentation -- !-- to determine if the login ends.